AI-driven PROTAC design overcomes oncogenic resilience by eliminating the CLIP1-LTK fusion protein.
The AI-guided development of a first-in-class proteolysis-targeting chimera (PROTAC) designed to selectively degrade the CLIP1-LTK fusion protein is reported, providing a promising therapeutic strategy for overcoming acquired resistance in kinase-driven cancers.
Shi-Cheng Chen, Hai-Ting Duan, S. Zhong et al.
· Proceedings of the National... · 0 citations